UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 340

Sortiert nach

Molnupiravir: From Hope to Epic Fail?

Viruses, 2022-11, Vol.14 (11), p.2560

Focosi, Daniele

2022

Link zum Volltext

Verfügbarkeit prüfen

A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance

Viruses, 2023-04, Vol.15 (5), p.1048

Focosi, Daniele

2023

Link zum Volltext

Verfügbarkeit prüfen

From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses

Vaccines (Basel), 2023-01, Vol.11 (1), p.109

Focosi, Daniele

2023

Link zum Volltext

Verfügbarkeit prüfen

Recombination in Coronaviruses, with a Focus on SARS-CoV-2

Viruses, 2022-06, Vol.14 (6), p.1239

2022

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern

The Journal of clinical investigation, 2023-03, Vol.133 (6), p.1-3

2023

Link zum Volltext

Verfügbarkeit prüfen

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

Viruses, 2022-09, Vol.14 (9), p.1999

2022

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Spike Protein Convergent Evolution: Impact of Virus Variants on Efficacy of COVID-19 Therapeutics and Vaccines

Focosi, Daniele

1st Edition 2021, 2021

Link zum Volltext

Verfügbarkeit prüfen

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence

Viruses, 2022-01, Vol.14 (2), p.187

2022

Link zum Volltext

Verfügbarkeit prüfen

Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab

Reviews in medical virology, 2019-11, Vol.29 (6), p.e2077-n/a

2019

Link zum Volltext

Verfügbarkeit prüfen

Convalescent Plasma Therapy for COVID-19: State of the Art

Clinical microbiology reviews, 2020-09, Vol.33 (4)

2020

Link zum Volltext

Verfügbarkeit prüfen

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2264

2023

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2488

2023

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review

International journal of molecular sciences, 2021-12, Vol.23 (1), p.29

2021

Link zum Volltext

Verfügbarkeit prüfen

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Nature communications, 2022-10, Vol.13 (1), p.6478-6478, Article 6478

2022

Link zum Volltext

Verfügbarkeit prüfen

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses

Viruses, 2023-04, Vol.15 (5), p.1063

2023

Link zum Volltext

Verfügbarkeit prüfen

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline

Viruses, 2022-11, Vol.14 (11), p.2488

2022

Link zum Volltext

Verfügbarkeit prüfen

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules

Viruses, 2023-03, Vol.15 (3), p.715

2023

Link zum Volltext

Verfügbarkeit prüfen

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

Emerging infectious diseases, 2021-10, Vol.27 (10), p.2728-2731

2021

Link zum Volltext

Verfügbarkeit prüfen

Acquired factor XIII deficiency after desensitization as a potential contributor to postoperative bleeding: more than meets the eye

Transplant international, 2015-02, Vol.28 (2), p.246-247

Focosi, Daniele

2015

Link zum Volltext

Verfügbarkeit prüfen

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma

International journal of infectious diseases, 2021-01, Vol.102, p.244-246

2021

Link zum Volltext

Verfügbarkeit prüfen

CD57+ T lymphocytes and functional immune deficiency

Journal of leukocyte biology, 2010-01, Vol.87 (1), p.107-116

2010

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Viruses, 2021-06, Vol.13 (7), p.1211

2021

Link zum Volltext

Verfügbarkeit prüfen

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

mAbs, 2020-01, Vol.12 (1), p.1854149-1854149

2020

Link zum Volltext

Verfügbarkeit prüfen

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy

Human vaccines & immunotherapeutics, 2023-08, Vol.19 (2), p.2260040-2260040

2023

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)

Emerging infectious diseases, 2022-05, Vol.28 (5), p.1083-1083

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 340

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(302)
Mit Volltextzugriff
(325)

Publikationsform

Artikel
(307)
Buchkapitel
(22)
Berichte
(9)
Bücher
(2)

Sprache

Englisch
(340)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(257)
Life Sciences & Biomedicine
(255)
Humans
(190)
Covid-19
(106)
Sars-Cov-2
(93)
Severe Acute Respiratory Syndrome Coronavirus 2
(70)
Virology
(66)
Infectious Diseases
(58)
Hematology
(49)
Immunology
(48)
Microbiology
(47)
Coronaviruses
(42)
Female
(38)
Male
(35)
Convalescent Plasma
(33)
Monoclonal Antibodies
(33)
Pandemics
(33)
Infections
(32)
Plasma
(31)
Viruses
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Molnupiravir: From Hope to Epic Fail?

A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance

From Co-Administration to Co-Formulation: The Race for New Vaccines against COVID-19 and Other Respiratory Viruses

Recombination in Coronaviruses, with a Focus on SARS-CoV-2

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment

SARS-CoV-2 Spike Protein Convergent Evolution: Impact of Virus Variants on Efficacy of COVID-19 Therapeutics and Vaccines

Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence

Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab

Convalescent Plasma Therapy for COVID-19: State of the Art

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge

SARS-CoV-2: Advances in Serological Methods and the Understanding of Antibody Escape

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Second-Generation SARS-CoV-2 Recombinants: Lessons from Other Viruses

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline

How SARS-CoV-2 Big Data Are Challenging Viral Taxonomy Rules

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

Acquired factor XIII deficiency after desensitization as a potential contributor to postoperative bleeding: more than meets the eye

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma

CD57+ T lymphocytes and functional immune deficiency

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy

High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response)

Suchergebnisse filtern